Tandem Diabetes Care has launched the latest version of the t:slim X2 insulin pump software, which is integrated with the DexCom G7 continuous glucose monitoring (CGM) system in the US.
Tandem’s automated insulin delivery (AID) system, featuring Control-IQ technology, is claimed to be the sole global option for AID that leverages Dexcom’s CGM technology.
The Dexcom G7 integration allows the t:slim X2 insulin pump users to spend more time in a closed loop, with minimal to no waiting time between Dexcom G7 CGM sensor sessions.
It can be used as either a Dexcom G6 or Dexcom G7 CGM sensor, providing more options for managing diabetes.
Related: Advanced Embolisation Procedure: Success with Zylox-Tonbridge’s GEKKO Coils
The Dexcom G7 is 60% smaller than the G6, with improved accuracy and a quicker 30-minute sensor warm-up time, compared to earlier two hours.
It also provides a 12-hour grace period for replacing sensors, facilitating smoother transitions between sessions, and providing flexibility in sensor change timing.
Tandem Diabetes Care president and CEO John Sheridan said: “With this launch we are offering more than 300,000 current t:slim X2 users the ability to integrate with Dexcom’s most advanced CGM technology, demonstrating our commitment to continued leadership in advancing AID systems.
“As we celebrate our ten-year partnership with Dexcom, we remain committed to sustaining our rapid pace of innovation to further our mission of helping improve the lives of people with diabetes.”
The company is currently shipping t:slim X2 pumps pre-loaded with the updated software to new customers.
The pump with Dexcom G7 integration is anticipated to be introduced in more countries worldwide, beyond the US, early next year.
In December 2022, Tandem Diabetes Care agreed to acquire Swiss medical equipment manufacturer AMF Medical.
AMF Medical’s Sigi Patch Pump has been designed for diabetes mellitus treatment and serves as an ergonomic, rechargeable patch pump for reducing the burden of managing diabetes.
